Kathryn R Taylor

List of Publications by Year
in descending order

14	3,969	623734	1058476
papers	citations	14 h-index	14 g-index

16	16	16	5554
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	How Support of Early Career Researchers Can Reset Science in the Post-COVID19 World. Cell, 2020, 181, 1445-1449.	28.9	43
2	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Communications Biology, 2019, 2, 156.	4.4	73
3	Electrical and synaptic integration of glioma into neural circuits. Nature, 2019, 573, 539-545.	27.8	706
4	IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. Journal of Pathology, 2018, 244, 242-253.	4.5	24
5	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 2018, 24, 1204-1215.	30.7	133
6	Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 31, 635-652.e6.	16.8	290
7	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	16.8	716
8	Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathologica, 2015, 130, 815-827.	7.7	482
9	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
10	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 2014, 46, 457-461.	21.4	423
11	ACVR1 Mutations in DIPG: Lessons Learned from FOP. Cancer Research, 2014, 74, 4565-4570.	0.9	76
12	Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN. Cancer Discovery, 2013, 3, 512-519.	9.4	264
13	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo. Clinical Cancer Research, 2013, 19, 5940-5951.	7.0	124
14	Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy. Clinical Cancer Research, 2012, 18, 796-807.	7.0	74